AM
Amgen
AMGN·NASDAQThousand Oaks CAFounded 198027,000 employees
Large CapbiotechPublicOncologyCardiologyImmunology
Platform: Bio & Bispecific
Market Cap
$160B
All Drugs
14
Clinical Trials
26
Failed / Terminated
1
FDA Approved
0
Stock Price & Catalysts (AMGN)
Loading AMGN stock data...
Drug Pipeline (14 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| AMG-1919 | AMG-1919 | Phase 2/3 | 2 | CDK2 | EpilepsyGBM | ||
| Polazasiran | AMG-8739 | Phase 2 | 2 | LAG-3 | MM | ||
| Fixazanubrutinib | AMG-4723 | Phase 2 | 1 | PI3Kα | TTR Amyloidosis | ||
| AMG-2752 | AMG-2752 | Preclinical | 2 | MDM2 | Heart FailureCRC | ||
| AMG-9654 | AMG-9654 | Phase 2 | 1 | GPRC5D | RBHuntington's | ||
| Sovacapivasertib | AMG-295 | Phase 3 | 4 | WEE1 | CFSchizophrenia | ||
| AMG-7379 | AMG-7379 | Preclinical | 2 | DLL3 | MGDravet | ||
| Motainavolisib | AMG-6567 | NDA/BLA | 2 | CD47 | PompeAngelman | ||
| AMG-4531 | AMG-4531 | Phase 2/3 | 2 | KRASG12C | CLL | ||
| AMG-415 | AMG-415 | Phase 1 | 2 | CDK2 | ETAsthma | ||
| Rimaosocimab | AMG-8762 | Preclinical | 1 | FXIa | FLDravet | ||
| AMG-2597 | AMG-2597 | Phase 2/3 | 2 | CD38 | CFCSU | ||
| AMG-9052 | AMG-9052 | Phase 2/3 | 2 | CDK2 | MigraineMM | ||
| Motavorutinib | AMG-491 | Phase 3 | 1 | CDK4/6 | LN |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (21)